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Summary.-Growth of transplanted rat tumours was retarded and in some cases
completely suppressed when cells were injected subcutaneously in admixture with
double stranded RNA (ds-RNA). This response required intimate contact between
ds-RNA and tumour cells and systemic treatment with the agent failed to prevent
progressive growth of a range of rat tumours. Direct cytotoxic effects of ds-RNA
may contribute to tumour suppression since the compound was cytotoxic in vitro
for cultured tumour cells. The involvement of host factors is suggested, however,
by the in vivo tests showing variations in susceptibility to ds-RNA mediated tumour
suppression similar to that previously observed with bacterial adjuvants.
DOUBLE-STRANDED RNA (ds-RNA),
both of natural origin (e.g. from fungal
virus) or prepared synthetically (e.g.
polyinosinic-polycytidylic acid, Poly I-C)
has been reported to exert tumour
suppressive effects in experimental
animals. For example, ds-RNA treat-
ment inhibits tumour development in
mice infected neonatally with murine
sarcoma virus (MSV) (De Clercq and
Merigan, 1971; Sarma et al., 1969), retards
development of polyoma virus induced
tumours in rats (Vandeputte et al., 1970)
and retards growth ofestablished grafts of
polyoma virus induced tumour in mice
(Fischer, Cooperband and Mannick, 1972).
Double-stranded RNA is a potent
stimulator of interferon production
(Planterose et al., 1970; Vandeputte et al.,
1970) and its control of virally induced
tumour has been interpreted as being
mediated by increased interferon pro-
duction (De Clercq and De Somer, 1971;
Vandeputte et al., 1970). However, ds-
RNA also exerts tumour suppressive
effects against some experimental tumours
in which no viral aetiologyisdemonstrable.
Thus, repeated interperitoneal adminis-
tration of ds-RNA retards or completely
prevents growth of the transplanted B16
melanoma (Bart and Kopf, 1969; Bart,
Kopf and Silagi, 1971; Kreider and
Benjamin, 1972) and Lewis lung carcinoma
(Heyes, Catherall and Harnden, 1974) in
C57B1 mice, and reduces their propensity
to metastasize. In addition Levy, Law
and Rabson (1969) have reported that
ds-RNA inhibits growth of a range of
transplanted mouse tumours, all of
spontaneous origin, including a reticulum
cell sarcoma, a fibrosarcoma and a
lymphoma. Treatment by intravenous
or intraperitoneal injection was effective
even if started several days after tumour
challenge, and established tumours could
be made to regress. Treatment also
retarded growth of a transplanted rat
mammary carcinoma (Kreider and
Benjamin, 1972), led to regression of
established grafts of3-methylcholanthrene
(Mc) induced mouse sarcomata (Fischer
et al., 1972), and inhibited growth of the
L1210 mouse leukaemia (Levy et al., 1960;
Zeleznick and Bhuyan, 1969). In a series
of tests with Mc induced lymphomata and
benzpyrene induced fibrosarcomata in
mice, Parr, Wheeler and Alexander (1973)
similarly found that ds-RNA retarded
subcutaneous and intradermal tumour
transplants, and often led to permanentTREATMENT OF TRANSPLANTED RAT TUMOURS. I
regressions. This effect was most marked
with intradermal tumour growths and
was generally most effective if delayed
until the animals had firmly established
tumours.
In contrast to the above reports,
systemic ds-RNA treatment has been
reported to have little or no protective
effect against many other experimental
tumours, and may even enhance their
growth. Thus, in contrast to the reports
of Fischer et al. (1972), Meier, Myers and
Huebner (1970) found that ds-RNA was
ineffective in the treatment of trans-
planted Mc induced murine sarcomata.
In addition, prolonged ds-RNA treatment
increased the incidence of primary
carcinogen induced thymic lymphomata
(Ball and McCarter, 1971.) although it
reduced the incidence ofradiation induced
lymphomata. Also, ds-RNA had little or
no effect on the induction of tumours by
SV40 virus in neonatal hamsters and did
not inhibit growth of SV40 induced
tumours transplanted into adult animals
(Larson, Panteleakis and Hilleman, 1970).
With Friend virus induced mouse leukae-
mia, while treatment several days after
virus infection led to a reduction in disease
treatment in the early stage of infection
increased its severity (Pilch and
Planterose, 1971). In addition, tumour
induction by MSV in mice was retarded in
very young (4-6 day old) mice by ds-RNA
treatment, but enhanced in 20-day old
animals (De Clercq and Merigan, 1971).
There is an indication, however, that, in
addition to its systemic effects, ds-RNA
may be more consistently suppressive if
injected directly into the environment of
tumour growth. Thus, intralesional
injections of ds-RNA restricted growth of
transplanted mouse tumours (Heyes et al.,
1974; Parr et al., 1973) and growth
of intraperitoneally injected mouse
lymphoma cells was more markedly
suppressed by intraperitoneal injection of
ds-RNA than when the material was given
by any other route (Ball and McCarter,
1971). In addition, growth of an ascitic
reticulum cell sarcoma was similarly
retarded by intraperitoneal injection of
ds-RNA (Levy et al., 1969).
In view of these conflicting reports on
the anti-tumour action of ds-RNA, the
present studies were carried out to assess
the influence of one standardized ds-RNA
preparation on the growth oftransplanted
rat tumours. These include tumours of a
number of different histological types,
ranging from highly immunogenic Mc
induced sarcomata to a chemically induced
mammary carcinoma with no detectable
immunogenic potential, and were selected
to allow an assessment of host immune
response in any inhibitory effects. In
addition, the ability of mixed inocula of
tumour cells and ds-RNA to induce
tumour specific immunity, and their
suitability as a vaccine for active immuno-
therapy, have been assessed, particularly
in comparison with previous studies with
BCG and tumour cell mixed inocula
(Baldwin and Pimm, 1973a).
MATERIALS AND METHODS
Double-stranded RNA.- Fungal virus ds-
RNA (Banks et al., 1969), was supplied by
Beecham Research Laboratories, Betchworth,
Surrey in ampoules containing approximately
50 mg offreeze-dried material (BRL 5907, lot
5/148). The contents of each ampoule were
reconstituted in water to 10 ml, sterilized by
filtration through a 0-22 Hum Millipore filter
and stored frozen at -20°C. The concen-
tration of ds-RNA in each preparation was
determined from optical density measure-
ments at 260 nm, with a 1 cm light path,
given that at 50 ,ug/ml EJ I'/ ,11 P0 (Plan-
terose, personal communication), further
dilutions being made in phosphate buffered
saline, pH 7-2.
Tumrours.-The tumours employed were
originally induced with chemical carcinogens
or arose spontaneously in rats of an inbred
Wistar strain. Each tumour was carried by
subcutaneous transplantation in syngeneic
rats of the same sex as the primary donor.
Sarcomata Mc7, Mc4OA and Mc57 induced by
subcutaneous injection of 3-methyleholan-
threne are strongly immunogenic; animals
immunized by excision of subcutaneous
growths rejecting challenge with whole
tumour grafts (Baldwin and Pimm, 1971;
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Baldwin et al., 1974). Hepatoma D23,
induced by oral administration of4-dimethy-
laminoazobenzene, is also immunogenic, pro-
ducing resistance following graft excision to
challenge with up to 5 x 105 tumour cells
(Baldwin and Barker, 1967; Price and Bald-
win, 1974). Mammary carcinoma AAF57
induced by repeated intraperitioneal injection
of N-hydroxy-2-acetylaminofluorene lacks
detectable immunogenicity, excision of sub-
cutaneous grafts failing to elicit resistance to
challenge with 1 x 103 cells, this being the
minimum inoculum for growth in control rats
(Baldwin and Embleton, 1974). Epithel-
ioma Spl arose spontaneously and is weakly
immunogenic, only5 x 104cellsbeingrejected
by immunized animals (Baldwin, 1966;
Baldwin and Embleton, 1974). Sarcoma
Sp24 which arose spontaneously is also
weakly immunogenic, immunized rats reject-
ing only 1 x 103 tumour cells.
Single-cell suspensions of tumours were
prepared by digestion of finely minced tissue
with 0 25% trypsin in Hanks' balanced salt
solution, washed and resuspended in medium
199.
Bacillus Catmette-Guerin (BCG).-Freeze-
dried BCG vaccine (percutaneous) was sup-
plied by Glaxo Research Ltd, Greenford,
Middlesex, England. The vaccine was recon-
stituted in water to 10 mg moist weight of
organisms./ml.
Experimental procedures.-Animals (150-
200 g body weight) receiving subcutaneous or
intradermal tumour cell inocula were treated
by 2-5 intraperitoneal injections of ds-RNA
(100-1000 ,ug) at 2-4 intervals. Treatment
was initiated at the same time as tumour cell
injection, or delayed for 10-26 days, when
rats had small tumour growths of 05-1-5 cm
mean diameter.
To test the influence of localized ds-RNA
on tumour growth, defined numbers of cells
suspended in medium 199 were mixed with
known amounts of ds-RNA diluted in phos-
phate buffered saline and immediately in-
jected subcutaneously. In some cases rats
rejecting mixed inocula of ds-RNA and tu-
mour cells were challenged 30-40 days later
with a further inoculum oftumour cells alone
at a contralateral subcutaneous site.
To assess the response to active immuno-
therapy, employing a vaccine of tumour cells
and either ds-RNA or BCG, animals receiving
a challenge inoculum of tumour cells alone
were treated with a simultaneous contra-
lateral injection of tumour cells mixed with
either ds-RNA or BCG organisms.
Assessment of tumour growth.-Subcut-
aneous or intradermal growths were measured
twice weekly with calipers and mean tumours
diameter calculated from measurements in
2 planes. The significance of the difference
between mean tumour diameters of treated
and control rats was assessed by Students
" t " test, and aP value assigned by reference
to standard tables. With epithelioma Spl,
pulmonary metastases were demonstrated by
perfusion of lungs with dilute India ink
(15% v/v) followed by fixation in Fekete's
solution (Wexler, 1966) and the number of
macroscopically visible nodules on the lung
surface counted.
In vitro cytotoxicity tests.-Tumour cell
culture lines were established from sarcomata
Mc7 and Mc57 and mammary carcinoma
AAF57 and maintained in Eagle's minimal
.essential medium (MEM) supplemented with
10% calf serum (CS). Tumour target cells
were plated in Cooke M29 ART Microtitre
plates at 100 or 200 cells per well in 0-2 ml
MEM + 10% CS. After 4-5 h incubation at
370C to allow cell attachment, the medium
was removed and wells washed twice with
0 3 ml PBS. ds-RNA solution 0 05 ml at
04-1 0 mg/ml, inPBS was addedto test wells,
and PBS alone to control wells. In some
tests ds-RNA solutions were mixed with an
equal volume of MEM or MEM + 10% CS
and control wells treated with PBS mixed
with MEM or MEM + 10% CS. Eight wells
were used for each treatment.
After 2 h incubation at370C, 0-2 ml MEM.
+ 10% was added to all wellsand platesincu-
bated for a further 2 days. The plates were
finally rinsed with PBS and the surviving
adherent cells were fixed with methanol; the
percentage inhibition of growth or survival
intestwells wasthen calculatedin comparison
with control wells. Statistical significance
between survival of cells in treated and un-
treated wells was assessed by student's " t"
test.
Some tests were performed with ds-RNA
solutions in PBS which had been dialysed for
18 h at +40C against PBS solution.
RESULTS
Influence ofsystemic administration
Table I shows the results oftests on the
systemic treatment of the transplanted
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TABLE I. Treatment ofTransplanted Hepatomna D23 with Double-stranded RNA
Treatment, (i.p.)
Dose
(rg)
5 x 100
Day*
10, 13, 16, 20, 22
4 x 100 16, 20, 22, 25
* With respect to tumour injection (1 x 105 cells).
hepatoma D23 with ds-RNA. In the
first test, subcutaneous tumour growths
were initiated by injection of 1 x 10 cells.
After 10 days, when animals had small
subcutaneous tumours (mean diameters
approximately 0 4 cm), they were injected
intraperitoneally with 100 ,ug of ds-RNA
and this was repeated at 2-4daysintervals,
a total of 5 doses being administered.
Treatment exerted no effect on tumours,
3
I-
LU ui
I-
a 2.
z
1
LU
progressive growth occurring in all treated
rats, at a rate identical with that in
control animals (Fig. 1). In the second
test hepatoma cells were injected intra-
dermally and animals treated with four
100 ,ag intraperitoneal injections of ds-
RNA, starting 16 days after tumour cell
injection when small (0.5 cm mean dia-
meter) intradermal tumours had
developed. Again, progressive growth
TIME (DAYS )
FiG. 1. Influeince of (Is-RNA on subcutanieous aI(l intra(leimal growrth of hepatoma D23. *
subcutaneous control growth; *A5 x 100 uig ds-RNA i.p. Days 10-22; *l * intra(lermal
control growth; V V 4 x 100 ,Ig ds-RNA i.p. Days 16-25.
11
Tumour
Mean
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Site
S.C.
I.D.
diameter
(cm)
0*4
0 5
0 5
0-6
No. of rats
wi'th
progressing
tumours
5/5
5/5
5/5
5/5M. V. PIMM, M. J. EMBLETON AND R. W. BALDWIN
TABLE II. Treatment of Transplanted Rat Tumours with Double-stranded RNA
Ttumour
Dose
(rig)
a x 100
Treatment (i.p.)
=- M.1
Dav*
10, 13, 17, 19, 22
X 250 15, 18, 22, 24, 26
4 x 1000 11, 13, 15, 17
5 x 250 14, 17, 21, 23, 25
5 x 500 14, 17, 21, 23, 25
5 x 100 0, 4, 7, 10, 13
3 x 500 20, 22, 27
2 x 5(10 26, 28
* With respect to ttumouir cell inijection.
occurred in both treated and control
animals, with no discernible difference in
growth rates (Fig. 1).
In the second series of tests (Table II),
with 3 Mc induced sarcomata, repeated
administration of ds-RNA again failed to
prevent progressive development of small
subcutaneous tumour growths, although
with sarcoma Mc7 repeated intraperi-
toneal injections of ds-RNA at 250 or
500 ,ug/dose significantly retarded tumour
growth compared with that in untreated
controls (Fig. 2).
The final tests (Table II) were carried
out with epithelioma Spl and the mam-
mary carcinoma AAF57. With epi-
thelioma Spl, rats were treated with 3
injections of 500 ,ug ds-RNA starting 20
days after subcutaneous tumour cell
injection, or five 100 ,ug doses starting on
the day of tumour cell inoculation. In
both cases tumour development continued
at rates comparable with those in control
rats. Finally, with the mammary
carcinoma AAF57, treatment of animals
bearing established 26-day old tumour
masses failed to prevent their progressive
development.
Influence of local administration
Table III summarizes the results of
tests on the tumour suppressive action of
ds-RNA when injected subcutaneously in
admixture with tumour cells. The first
series of tests (Experiments 1-5) were
carried out with 3 Mc induced sarcomata
and with each progressive tumour growth
was prevented by admixturewithds-RNA.
In the test (Experiment 5) with sarcoma
Mc52A, admixture of 100 ,Ig ds-RNA to
an inoculum of 1 X 106 cells successfully
prevented progressive groxvth in all rats,
although in this case small tumour
growths developed in all treated animals,
reached approximately 1 cm mean dia-
meter by 30 davs and then underwent
regression.
In tests with the second tumour type
examined, hepatoma D23, addition of
100 p,g ds-RNA to inocula of 5 x 103-
1 X 105 cells prevented their subcutaneous
development in all but one of 18 rats,
compared with growth in all controls
(Experiments 6-8). Similarly, with the
spontaneous fibrosarcoma Sp24, ad-
mixture of 2 x 104-5 x 104 cells with
100-500 pig ds-RNA prevented growth in
Tumour
type
Sarcoma
Mc4OA
Sa'rcoma
Mc57
Sarcoma
Mc57
Sarcoma
Mc7
Epithelioima
SPI
Epithelioma
SPi
Mammary
carcinoma
AAF57
No. of
cells
injecte(l
1 X 106
1 x 106
1 x 106
2 x 106
2 x 1(4
1 x 106
1 X 1()4
AMeaii
(liameter
(cm)
0 6
0o5
0 5
0*5
0 6
0 7
0 7
0 6
0 7
0 5
0 5
0 4
0 5
No. of rats
wi'th
progressinlg
tlIf)lTIoUS
5/5
5/5
4/4
4/4
4/4
5/5
5/5
5 5
5/5
5/5 31/3
4/4
5/5
5/5r)
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LU
+1
E
0
LU
LU
0
0
z
LU
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TIME (DAYS)
FIG. 2. Inifluence ofd1s-RNA on subcutaneous growth of sarcoma Mc7. * * controls; *l *
5 x 250 ,ug (1s-RNA i.p. Days 14-25; A A 5 x 500 ,Ig ds-RNA i.p. Days 14-25. P < 0 05
at Days 20 and 22 for both treated groups.
TABLE III. Subcutaneous Growth of Tumour Cells
with Double-stranded RNA
Mixedl inoculum
Experiment
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Tumour
Sarcoma Mc7
Sarcoma Mc57
Sarcoma Mc52A
Hepatoma D23
Sarcoma Sp24
Epithelioma Spl
Mammary
carcinoma AAF57
* Tumours developed and regressed.
t Growth retarded.
No. of
cells
1 X 106
1 X 106
1 X 106
2 x 106
1 X 106
5 x 103
1 x 105
1 x 105
2 x 104
2 x 104
5 x 104
1 x 105
1 104
1 104
ltg ds-RNA
100
100
100
250
100
100
100
100
100
500
125
100
100
250
Injected in Admixture
Tumour takes in:
Treated Controls
0/4 4/4
0/5 5/5
0/4 4/4
0/5 4/4
0/5* 5/5
0/4 4/4
1/5 5/5
0/9 9/9
2/5 4/5
1/5 5/5
0/4 4/4
6/6t 6/6
4/6t 6/6
4/5 5/5
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the majority (11/14) of animals (Experi-
ments 9-11).
In the test with epithelioma Spl
(Experiment 12), while growth from an
inoculum of 1 x 105 cells was not pre-
vented by admixture with 100 ,ag ds-RNA,
tumour growth was markedly retarded
compared with control animals so that
palpable tumours appeared later but then
developed at a rate comparable with that
from tumour cells alone. However,
similar numbers of pulmonary metastases
were present in both groups of rats, with
4-200 + nodules (mean 50) in treated
animals and with 10-200 + nodules (mean
40) in 5/6 control rats with macroscopically
visible metastases.
With mammary carcinoma AAF57,
growth from an inoculum of 1 x 104 cells
was also prevented in a proportion of
animals by admixture with ds-RNA and
tumour growth was retarded in the
remaining rats (Experiments 13 and 14).
For example, in Experiment 13 growth
occurred in 6/6 control animals whereas
retarded growth occurred in only 4/6
o 3-
LU
I-
LU :E
O 2-
ad
D
0
1. z
LU
animals receiving mixed inocula of cells
and ds-RNA (Fig. 3).
Induction of immunity following rejection
of mixed inocula of tumour cells and
ds-RNA
Rats rejecting mixedinocula oftumour
cells and ds-RNA were subsequently
challenged with cells of the same tumour
and, as shown in Table IV, little or no
tumour immunity was detectable. Thus,
rejection of 1 x 105 hepatoma D23 cells
protected 4/9 animals against a subsequent
challenge of 5 x 105 hepatoma D23 cells,
but a challenge of 1 x 104 cells was not
rejected in 2/2treatedanimals. Similarly,
with the sarcoma Mc57, rejection of
2 x 106 cells with ds-RNA protected only
2/5 rats against challenge with 1 x 106
cells. With sarcoma Mc7, in 3 separate
tests (Experiments 4-6), rats rejecting
1 x 106 cells and ds-RNA consistently
failed to reject a challenge of the same
number of cells alone, the inoculum
developing in all treated and control
animals. In the final tests (Experiments
46 6
TIME ( DAYS )
FRI. 3.-Growth of mammary carcinoma AAF57 cells injected subcutaneously alone *-
admixture with 100 lug ds-RNA * *.
-0 or in
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TABLE IV.-Tumour Transplantation Resistance in Rats Rejecting Mixed
Inocula of Tumour Cells and Double-stranded RNA
Treatment inoculum
rA_ Ak
Experiment
1
2
3
4
5
6
7
8
9
Tumour
Hepatoma D23
Sarcoma Mc7
Sarcoma Me57
Sarcoma Sp24
No. of
cells
1 x 105
1 X 105
1 X 105
1 X 106
1 X 106
1 X 106
2 x 106
2 x 104
5 x 104
8 and 9), with sarcoma Sp24, rats rejecting
2 X 104 or 5 x 104 cells in admixture
with ds-RNA were not immune to
challenge with the same cell numbers.
Active immunotherapy
Although injection of cells of sarcoma
Mc7 together with ds-RNA did not protect
against a subsequent challenge with Mc7
cells, 2 further tests were carried out to
examine the use of mixed inocula for
active immunotherapy of a simultaneous
challenge of tumour cells alone at a
distant site, particularly to compare the
effectiveness of this treatment with that
known to be produced with mixed inocula
of Mc7 cells and BCG organisms (Baldwin
and Pimm, 1973a). In these tests (Table
V) rats received a challenge inoculum of
1 x 106 sarcoma Mc7 cells subcutaneously
on one side ofthe body and a contralateral
subcutaneous injection of Mc7 cells
together with 100 ,tg ds-RNA or 100-500
,ug BCG organisms. The mixed inocula of
TABLE V. Active Immunotherapy of
Tumour Cells and Doubl,
Treatment inoculum
! K~~~~~~~~
Experiment
1
2
Admixed with:
No. of ,A_
cells Material ,ug
1 x 106 ds-RNA 100
1 x 106 BCG 100
I x 106 ds-RNA 100
1 x 106 BCG 500
lug ds-RNA
100
100
100
100
100
100
250
100
125
No. of
cells
5 x 103
5 x 103
1 X 104
1 X 106
1 X 106
1 X 106
1 X 106
2 x 104
5 x 104
Challenge inoculum
I
Takes in:
Test Control
3/4 5/5
2/5 4/5
2/2 4/5
4/4 4/4
4/4 4/4
5/5 6/6
3/5 4/4
4/4 4/5
3/4 3/5
cells and ds-RNA failed to develop in all
animals but there was no simultaneous
rejection of the contralateral challenge
inoculum of cells alone in either of 2
separate experiments. In contrast,
growth of the challenge inoculum was
successfully prevented in both tests in a
total of 9/10 rats treated with a mixed
inoculum of sarcoma Mc7 cells together
with BCG.
Cytotoxicity tests
In view of the marked tumour sup-
pressive effect of ds-RNA injected in
admixture with tumour cells, further tests
were carried out to assess the direct effect
of ds-RNA on in vivo and in vitro growth
potential of tumour cells.
In these tests (Table VI), tumour cells
were suspended in ds-RNA, at a concen-
tration of 1 mg/ml in medium 199 and
incubated at 37°C for 3 h. Cell sus-
pensions were then either diluted directly
in medium 199 to thedesired concentration
Sarcoma Mc7 with Mixed Inocula of
'e-stranded RNA or BCG
Contralateral challenge inoculum
Takes in:
No. of
cells
1 X 106
1 X 106
1 X 106
1 X 106
Treated
rats Controls
4/4 4/4
0/6 5/5
5/5 5/5
1/5 5/5
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TABLE VI.-Subcutaneou-s Growth of Tumour Cells Treated with Double-stranded RIVA
Ttumotur takes in:
Experiment Tumour Inocllotlm Test Conitrols
1 Hepatoma D23 1 x 105 cells + 20 jig (Is-RNA 0/5 5/5
1 X 105 cells treate(l with dls-RNA* 0/5
2 Hepatoma D23 1 x 105 cells + 100 fAg ds-RNA 2/5 5/'S
1 X 105 cells treatedl vith (ls-RNA 2/5
3 Sarcoma Mc7 1 x 106 cells + 200 ,ig ds-RNA 0/4 4/4
1 x 106 cells treate(l with (ls-RNA 1/3
* Cells incubated 3 h in 1 mg/ml ds-RNA, wrashed in medium 1399 before inijection.
of cells and ds-RNA for injection, or
washed 3 times in medium 199 before
re-counting and dilution. Over 9000 of
cells in both preparations excluded trypan
blue on microscopical examination but in
vivo growth was prevented or retarded
with both tumour types examined (Table
VI). For example, with hepatoma D23,
admixture of 1 x 105 cells with 20 ,g
ds-RNA prevented progressive growth of
cells in all rats, and similarly no growth
was produced from the same cell number
washed free of ds-RNA.
The tests shown in Table VII were
carried out to examine the in vitro
cytotoxicity of ds-RNA for cultured
tumour cells. Most of these tests were
carried out by exposing plated cells to
ds-RNA in serum-free medium since there
is an indication (Heyes et al., 1974) that
serum nucleases may destroy ds-RNA.
With all 3 tumours examined, ds-RNA
treatment significantly reduced tumour
cell survival. In the first 2 tests with
sarcoma Mc7, exposure to ds-RNA (1 mg/
ml in PBS) reduced the survival of cells by
96-100o compared with control wells
exposed to PBS alone. Comparable
results were obtained with sarcoma Mc57,
ds-RNA treatment reducing survival by
66-99%. In 2 further tests with sarcomca
Mc57, the cytotoxicity ofds-RNA solution
previously dialysed against PBS was
examined and here, too, significant
reduction in cell survival was observed,
even in the presence of serum containing
medium. The final tests with mammary
carcinoma AAF57 showed a similar
significant cytotoxicity of ds-RNA for
tumouir cells.
D)ISCUlSSION
These studies demonstrate that a
naturally occurring double stranded RNA
of fungal virus origin (Beecham's BRL
5907) will suppress or retard the growth of
TABLE VII. In vitro Cytotoxicity of Double-stranded RNA for Cultured
Tumour Cells
(Is-RNA exposure
- A
Tumotir
Sarcoma AMc7
Sarcoma MTc57
corIc
,ligml
1000
1()00
1000
1000
400t
400.
Medelitum
PBS
PBS
PBS
PBS
PBS
PBS:
MEM 1A , C() 0s
7 Mammary 1(00 P1
8 carcinoma AAF57 I 00() P1
* Cells expose(l to me(lium alone.
t All values significant, P < 0 05.
T Double strandledl RNA soltution (lialyse(I againist PBS.
B3S
135
No. of survixving
cells + s.e.
Contrlol* Test
4-3 -- (6 2 1
119 7 0
77 - 7 26 ± 7
96 9 9 0 5 ) 0:3
34 61 (; 12 -- 3
6:3 . 5 29_ 3
Test
1
2
:3
4
5
6
o/
Inhibitionlt
96
100
66
99
65
54
34 9 24 1:I1
49 4 6 1 87
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a ranige of syngeneically transplanted rat
tumours, including spontaneous and
chemically induced sarcomata, a hepatoma
and a mammary carcinoma, if injected
subcutaneously in admixture with tumour
cells although the material is essentially
inactive on systemic injection. The most
marked suppression was obtained with
highly immunogenic Mcinduced sarcomata
and the hepatoma D23, although with 3
other tumours retardation of growth
from cell inocula was observed. A
similar suppression of growth of these
tumours has previously been reported
when cells were injected in admixture with
intact BCG organisms (Baldwin and
Pimmrl, 1971, 1973a) or mycobacterial
methainol extraction residue (Hopper,
Pimm and Baldwin, 1976). In contrast
to the findings with mycobacterial pre-
parations, however, animals rejecting
mixed inocula of cells of immunogenic
sarcomata or hepatoma D23 were not
consistently immune to further challenge.
This is most obvious in the case ofsarcoma
Mc7, where animals rejecting mixed
inocula of I x 106 cells and ds-RNA,
consistently failed to reject a further
challenge with I x 106 cells of the same
tumour. In addition, animals rejecting
mixed inocula oftumour cells and ds-RNA
failed to suppress growth of a simul-
taneous contralateral injection of tumour
cells, whereas mixed inocula of sarcoma
cells and BCG can successfully control
growth of distant subcutaneous challenge
inocula (Baldwin and Pimm, 1971, 1973a).
It is probable that the local tumour
suppressive property of the ds-RNA
preparation used in these studies is due, at
least in part, to a direct effect of the
material upon tumour cells. Cells in-
cubated in ds-RNA and then washed
failed to grow in vivo, although the
viability ofthe cells at the time ofinjection
was not affected, at least as assessed by
trypan blue exclusion tests. The present
tests also demonstrate that exposure of
tumour cells to ds-RNA restricted their
in vitro survival. Dialysis of ds-RNA
against PBS did not reduce cytotoxicity,
indicating that the effect was not due to
osmotic imbalances or the presence of
cytotoxic small molecular weight com-
ponents.
It is not possible, however, to ascribe
the in vivo suppression of tumour growth
only to indiscriminate cytotoxicity of the
material, since tumours vary markedly in
their in vivo susceptibility to this treat-
ment. For example, with the carcinogen
induced mammary carcinoma AAF57,
only retardation of growth was achieved
with as few as 1 x 104 cells in admixture
with ds-RNA, whereas with carcinogen-
induced sarconiata at least 2 x 106 cells
were prevented from growth. Further-
more, temporary growth of tumour
cell-ds-RNA mixed inocula was sometimes
observed, followed by regressions. The
degree of ds-RNA mediated tumour
suppression described in this paper is
similar to that previously reported in
comparable tests with BCG. Here, too,
injection of BCG together with tumour
cells restricts or prevents their develop-
ment, but tumours vary markedly in their
susceptibility (Hopper et al., 1975). The
mechanism of this suppression with BCG
probably involves activation of host
macrophages, since the effect is not
altered by immunosuppression (Pimm and
Hopper, 1975), but is abrogated by silica
induced host macrophage depletion (Pimm
and Hopper, 1975; Hopper et al., 1976).
Double stranded RNA, like BCG, has been
shown to be macrophage activating,
rendering them cytotoxic for malignant
cells (Alexander and Evans, 1971).
Further tests are therefore in progress
with the experimental tumours described
here to assess the influence of host
macrophage depletion and immuno-
suppression on contact suppression of
tumour growth by ds-RNA.
The mode of action of ds-RNA in the
type of tumour suppression described
here clearly requires further investigation
but the studies indicate that treatment
with the ds-RNA preparation employed
(Beecham's BRL 5907) might be extended
to tumours at other sites. Extensive
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experimental studies with BCG (Baldwin
and Pimm, 1973b, c, 1974; Pimm and
Baldwin, 1975) have indicated that
adjuvant contact therapy can be used to
control pulmonary metastases and tumour
deposits in the pleural and peritoneal
cavities. These latter tests have been
carried out to assess the application of the
form of treatment to the clinical manage-
ment of mesothelioma in man, in view of
the inadequacy of conventional therapy in
controlling the disease (Elmes, 1973).
Further tests have therefore been carried
out with BRL 5907 to determine its
influence on intraperitoneal and intra-
pleural tumour growths, the indication
from these further studies (Pimm and
Baldwin, 1976) being that this material
may be as efficient as BCG in suppressing
tumour growth at these sites.
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